“GlaxoSmithKline has first option on commercialisation of ISIS antisense drugs.”
ANP’s partnership with ISIS for ALT1102/3 could see us at the negotiating table of GlaxoSmithKline for commercialisation.
ISIS is very cashed up right now with 470 million at call and i bet they will want a bigger share of ALT1103.... ANP could very well have all the funding they ever want with these upcoming results as they contain independently certified IGF-I reduction levels which is proof of concept PoC.
These drugs have an easy path to market no doubt about it GSK will see things move fast for ANP!
I think the big bang may be even closer than i first thought.... not hard to work out why the directors buying?!!
JMO and Good Luck!
ANP Price at posting:
10.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)